You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 13, 2025

Drugs in MeSH Category Anticoagulants


✉ Email this page to a colleague

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sandoz ENOXAPARIN SODIUM (PRESERVATIVE FREE) enoxaparin sodium INJECTABLE;SUBCUTANEOUS 077857-002 Jul 23, 2010 AP RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Sanofi Aventis Us HEDULIN phenindione TABLET;ORAL 008767-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Pfizer FRAGMIN dalteparin sodium INJECTABLE;SUBCUTANEOUS 020287-006 Apr 4, 2002 RX Yes Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Amphastar Pharm ENOXAPARIN SODIUM (PRESERVATIVE FREE) enoxaparin sodium INJECTABLE;SUBCUTANEOUS 076684-006 Sep 19, 2011 AP RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Shenzhen Techdow ENOXAPARIN SODIUM (PRESERVATIVE FREE) enoxaparin sodium INJECTABLE;SUBCUTANEOUS 205660-005 Mar 15, 2023 AP RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Amphastar Pharm ENOXAPARIN SODIUM (PRESERVATIVE FREE) enoxaparin sodium INJECTABLE;SUBCUTANEOUS 076684-002 Sep 19, 2011 AP RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Anticoagulants Market Analysis and Financial Projection

The global anticoagulants market is experiencing robust growth, driven by rising cardiovascular diseases and innovative therapies, while facing transformative shifts from upcoming patent expirations and interdisciplinary advancements in drug development. Valued at $33.93 billion in 2024, the market is projected to reach $81.16 billion by 2034 (9.63% CAGR)[1][5], with Direct Oral Anticoagulants (DOACs) like rivaroxaban and apixaban currently dominating the landscape[2][11].

Market Dynamics

Growth Drivers

  • Cardiovascular Epidemic: 17.9M annual global deaths from cardiovascular diseases drive demand[5]
  • Aging Populations: 30% of U.S. heart attack survivors face recurrence risks requiring long-term anticoagulation[5]
  • Obesity Crisis: Global obesity rates increasing clot-related comorbidities[5]
  • Surgical Demand: Hip/knee replacements requiring perioperative anticoagulation[6]
Regional Analysis Region 2024 Market Share Key Growth Factors
North America $18.05B[1] Advanced healthcare, 9.63% CAGR through 2034
Asia-Pacific Fastest growing 8.2% CAGR in China, rising CVD awareness[1][5]
Europe Steady growth CVD causes >50% mortality, UK/Germany lead[1]

Therapeutic Segmentation

  1. DOACs (58% market share): Rivaroxaban/Xarelto ($4.4B sales, patent expiring Feb 2025)[18]
  2. Heparins: Eco-friendly synthesis innovations emerging[2]
  3. Vitamin K Antagonists: Warfarin generics dominate developing markets[11]

Patent Landscape & Innovation

2025 Patent Cliff
Major anticoagulants losing protection:

Drug Company 2023 Sales Key Patents Expiring
Xarelto Janssen $4.4B US7157456B2 (Feb 2025)[18]
Eliquis BMS/Pfizer Blockbuster EP1427415 (UK appeal ongoing)[17]
Pradaxa Boehringer $1.9B Composition patents 2025[15]

Innovation Frontiers

  1. AI-Driven Discovery: Machine learning models predicting FXa inhibitors with 92% accuracy[10]

  2. Device-Drug Hybrids:

    • LAAC Devices: 98.5% implant success rate in trials[14]
    • Smart Dispensers: Bluetooth-enabled warfarin trackers[2]
  3. Sustainability Focus:

    • Closed-loop heparin synthesis reducing 40% solvent waste[2]
    • Biodegradable nanoparticle carriers[12]

Legal Challenges
The UK Court of Appeal's 2023 ruling on apixaban patents established stricter "plausibility" standards, requiring demonstrated biological mechanism in filings[17]. This precedent impacts 22 pending DOAC patent applications globally.

Future Outlook

The market will bifurcate into two streams by 2030:

  1. Generic Competition: 78% price reduction expected for Xarelto generics post-2025[18]
  2. Next-Gen Therapies:
    • Gene Editing: CRISPR-based Factor IX inhibitors in Phase II trials
    • Biosensor Integration:
      def dose_adjust(real_time_coag):
       if coag > 2.5: return reduce_dose(25%)
       else: return maintain_regimen()

      AI-guided dosing algorithms patent activity up 300% since 2021[9]

"The anticoagulant revolution will be personalized – where your genome and smartwatch data dictate your clot prevention strategy." - Industry Analyst[12]

R&D Investment Hotspots

  • Biomaterial Interfaces: Heparin-coated stents with 30% lower restenosis rates
  • CircRNA Therapies: Long-lasting factor inhibitors requiring monthly dosing

This evolving landscape presents both challenges from generics and unprecedented opportunities through convergent technologies, reshaping thrombosis management fundamentally.

References

  1. https://www.precedenceresearch.com/anticoagulants-market
  2. https://patentpc.com/blog/patenting-innovations-anticoagulants-blood-thinner
  3. https://www.ncbi.nlm.nih.gov/sites/entrez?Db=mesh&Cmd=DetailsSearch&Term=%22Acenocoumarol%22%5BMeSH+Terms%5D
  4. https://patents.google.com/patent/WO2015086618A1/en
  5. https://www.researchandmarkets.com/reports/6050575/anticoagulants-market-forecasts
  6. https://www.transparencymarketresearch.com/anticoagulants-marke.html
  7. https://www.wipo.int/edocs/pubdocs/en/patents/946/wipo_pub_946.pdf
  8. https://www.ncbi.nlm.nih.gov/mesh?Db=mesh&Cmd=DetailsSearch&Term=%22Heparin%22%5BMeSH+Terms%5D
  9. https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0077142
  10. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1105880/full
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC5906253/
  12. http://www.sioc.ac.cn/lib/inforres/resources/202406/P020240624366379933576.pdf
  13. https://aspe.hhs.gov/reports/market-barriers-development-pharmacotherapies-treatment-cocaine-abuse-addiction-final-report
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC11167726/
  15. https://biopharmaapac.com/analysis/60/5727/25-high-value-drugs-losing-patent-protection-in-2025-what-it-means-for-healthcare.html
  16. https://www.pharmamanufacturing.com/home/article/55249347/key-drugs-losing-patent-protection-in-2025
  17. https://www.osborneclarke.com/insights/pharma-industry-watches-uk-court-appeal-considers-issue-plausibility
  18. https://www.greyb.com/blog/drug-patents-expiring/
Last updated: 2025-03-24

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.